Discipline(s): Épidémiologie, vaccins, modélisation, maladies émergentes, économie de la santé
Current position: Professeur de l'EHESP, en Épidémiologie et Biostatistiques, spécialiste de la dynamique des maladies transmissibles, coordinateur du cours d'Épidémiologie de terrain IDEA
Diploma(s): Doctorat
Affiliation(s): Département Méthodes quantitatives en santé publique (METIS), Department of Quantitative Methods in Public Health, UMR 6051 ARENES-CRAPE
Curriculum
Dr. Pascal Crépey, Professor at the French School of Public Health, focuses his research on pivotal areas within epidemiology and biostatistics. With expertise spanning infectious disease modeling, epidemiological surveillance utilizing big data, and the economic aspects of preventive health strategies, Dr. Crépey is at the forefront of public health research.
He holds a PhD in biomathematics and biostatistics from Université Pierre et Marie Curie, Paris.
Tenured researcher and lecturer in the Health Services Research Team (RSMS – Inserm U 1309), within Unité Mixte de Recherche Arènes - UMR 6051 (EHESP, Université de Rennes, CNRS, IEP Rennes).
Co-authors of more than fifty scientific articles published in peer-reviewed international journals.
Research
For more than two decades, Dr. Crépey has studied the intricacies of influenza dynamics, making substantial contributions to our understanding of its epidemiological mechanisms. In response to the COVID-19 pandemic, it quickly redirected its efforts to analyze its dynamic nature and evaluate the effectiveness of various mitigation strategies. His recent research explores the complex interplay between COVID-19, RSV, and influenza, particularly focusing on the potential impact of non-pharmaceutical interventions on the trajectories of these epidemics.
At the same time, Dr. Crépey spent several years studying the dynamic structure of health networks and its influence on the spread of antibiotic-resistant bacteria at regional, national and transnational levels. Its objective is to propose effective strategies to control the spread of these bacteria, thus responding to a major public health concern.
PhD candidate position offer: description
Application due no later than June 1st, 2024
Recent publications (last 30):
[1] Smith DRM, Jijón S, Oodally A, et al. Sick leave due to COVID-19 during the first pandemic wave in France, 2020. Occup Environ Med 2023; 80: 268–272.
[2] Roux J, Massonnaud C, Colizza V, et al. Modeling the impact of national and regional lockdowns on the 2020 spring wave of COVID-19 in France. Scientific Reports; 13.
[3] Boudewijns B, Paget J, Del Riccio M, et al. Preparing for the upcoming 2022/23 influenza season: A modelling study of the susceptible population in Australia, France, Germany, Italy, Spain and the United Kingdom. Influenza Resp Viruses; 17. Epub ahead of print January 2023. DOI: 10.1111/irv.13091.
[4] Velardo F, Bouziri H, Adélaïde L, et al. A cross-sectional study on infectious health risks regarding freshwater sports practice in Brittany, France. Journal of Water and Health 2022; 20: 356–368.
[5] Raude J, Xiao C, Crépey P. Revisiting the primary bias: the role of innumeracy in the misperception of prevalence of chronic illnesses. null 2022; 1–19.
[6] Pinquier D, Crépey P, Tissières P, et al. Preventing Respiratory Syncytial Virus in Children in France: A Narrative Review of the Importance of a Reinforced Partnership Between Parents, Healthcare Professionals, and Public Health Authorities. Infect Dis Ther. Epub ahead of print 15 December 2022. DOI: 10.1007/s40121-022-00737-2.
[7] Paireau J, Andronico A, Hozé N, et al. An ensemble model based on early predictors to forecast COVID-19 health care demand in France. Proceedings of the National Academy of Sciences 2022; 119: 8.
[8] Massonnaud CR, Roux J, Colizza V, et al. Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study. Vaccines 2022; 10: 479.
[9] Lemaitre M, Fouad F, Carrat F, et al. Estimating the burden of influenza‐related and associated hospitalizations and deaths in France: An eight‐season data study, 2010–2018. Influenza Resp Viruses 2022; irv.12962.
[10] Janssen C, Mosnier A, Gavazzi G, et al. Coadministration of seasonal influenza and COVID-19 vaccines: A systematic review of clinical studies. Human Vaccines & Immunotherapeutics 2022; 2131166.
[11] Gavazzi G, Mosnier A, Crepey P, et al. Vaccin grippal haute dose : un vaccin adapté aux 65 ans et plus. La Presse Médicale Formation 2022; 3: 105–118.
[12] Foucrier A, Perrio J, Grisel J, et al. Transition matrices model as a way to better understand and predict intra-hospital pathways of covid-19 patients. Sci Rep 2022; 12: 17508.
[13] de Fougerolles TR, Damm O, Ansaldi F, et al. National influenza surveillance systems in five European countries: a qualitative comparative framework based on WHO guidance. BMC Public Health 2022; 22: 1151.
[14] de Bouillé JG, Nguyen LBL, Crépey P, et al. Transmission of SARS-CoV-2 during indoor clubbing events: A clustered randomized, controlled, multicentre trial protocol. Frontiers in Public Health 2022; 11.
[15] Crépey P, Noël H, Alizon S. Challenges for mathematical epidemiological modelling. Anaesthesia Critical Care & Pain Medicine 2022; 41: 101053.
[16] Crépey P, Massonnaud C. [Covid-19 : un pari épidémiologique perdu ?]. Rev Prat 2022; 72: 523–525.
[17] Boudewijns B, Paget J, Del Riccio M, et al. Preparing for the upcoming 2022/23 influenza season: A modelling study of the susceptible population in Australia, France, Germany, Italy, Spain and the United Kingdom. Influenza Resp Viruses 2022; irv.13091.
[18] Zeevat F, Crépey P, Dolk FCK, et al. Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program. Value in Health 2021; 24: 3–10.
[19] Tran Kiem C, Massonnaud CR, Levy-Bruhl D, et al. A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures. EClinicalMedicine 2021; 38: 101001.
[20] Tran Kiem C, Crépey P, Bosetti P, et al. Lockdown as a last resort option in case of COVID-19 epidemic rebound: a modelling study. Eurosurveillance; 26. Epub ahead of print 3 June 2021. DOI: 10.2807/1560-7917.ES.2021.26.22.2001536.
[21] Tran Kiem C, Bosetti P, Paireau J, et al. SARS-CoV-2 transmission across age groups in France and implications for control. Nat Commun 2021; 12: 6895.
[22] Roux J, Nekkab N, Colomb-Cotinat M, et al. Time-series modelling for the quantification of seasonality and forecasting antibiotic-resistant episodes: application to carbapenemase-producing Enterobacteriaceae episodes in France over 2010–20. Journal of Antimicrobial Chemotherapy 2021; 76: 226–232.
[23] Rigoine de Fougerolles T, Puig‐Barbera J, Kassianos G, et al. A comparison of coronavirus disease 2019 and seasonal influenza surveillance in five European countries: France, Germany, Italy, Spain and the United Kingdom. Influenza Other Respi Viruses 2021; irv.12941.
[24] Moutchia J, Njouom R, Rumpler E, et al. Maternal age at first childbirth and geographical variation in HBV prevalence in Cameroon: Important role of mother-to-child transmission. Clinical Infectious Diseases 2021; ciab548.
[25] Di Domenico L, Sabbatini CE, Boëlle P-Y, et al. Adherence and sustainability of interventions informing optimal control against the COVID-19 pandemic. Commun Med 2021; 1: 57.
[26] Temime L, Gustin M-P, Duval A, et al. A Conceptual Discussion About the Basic Reproduction Number of Severe Acute Respiratory Syndrome Coronavirus 2 in Healthcare Settings. Clinical Infectious Diseases 2020; ciaa682.
[27] Roux J, Massonnaud C, Crépey P. COVID-19: One-month impact of the French lockdown on the epidemic burden. Preprint, Epidemiology. Epub ahead of print 27 April 2020. DOI: 10.1101/2020.04.22.20075705.
[28] Nekkab N, Crépey P, Astagneau P, et al. Assessing the role of inter-facility patient transfer in the spread of carbapenemase-producing Enterobacteriaceae: the case of France between 2012 and 2015. Sci Rep 2020; 10: 14910.
[29] Massonnaud C, Roux J, Crépey P. COVID-19: Forecasting short term hospital needs in France. Preprint, Epidemiology. Epub ahead of print 20 March 2020. DOI: 10.1101/2020.03.16.20036939.
[30] Crépey P, Redondo E, Díez-Domingo J, et al. From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain. PLoS ONE 2020; 15: e0233526.
Expertise
Member of the ANRS-MIE Coordinated Actions "Modeling of Infectious Diseases" and "Vaccines against respiratory viruses".
Courses
Head of the field epidemiology training course IDEA.